Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Elena Giubellino"'
Autor:
Davide Ottaviani, Alessandro Comandone, Antonella Boglione, P. Bergnolo, Raimondo Piana, Elena Giubellino, Veronica Prati, F. Garetto, P. Pochettino, Simona Chiadò Cutin, Orietta Dal Canton
Publikováno v:
Journal of Clinical Oncology. 35:e22528-e22528
e22528 Background: Elderly people represent more than 50% of STS patients, but few data are available in this population and old patients in clinical studies are underrepresented or not included. Aim of this retrospective, monoinstitutional study is
Autor:
P. Pochettino, F. Garetto, Simona Chiadò Cutin, Elena Giubellino, Davide Ottaviani, Maria Luisa Sartori, Orietta Dal Canton, P. Bergnolo, C. Oliva, Alessandro Comandone, Antonella Boglione
Publikováno v:
Journal of Clinical Oncology. 32:e11547-e11547
e11547 Background: Fulvestrant (F) is a pure antiestrogen drug approved for MBC of postmenopausal women with estrogen receptor positive disease. The CONFIRM trial has recently demonstrated that a double dose (500 mg/monthly) of F is superior to 250 m
Autor:
F. Garetto, Alessandra Linari, Simona Chiadò Cutin, M. Turbiglio, Antonella Boglione, Orietta Dal Canton, Alessandro Comandone, Raimondo Piana, Elena Giubellino, P. Pazienza, G. Gino, P. Pochettino, P. Bergnolo, C. Oliva, Davide Ottaviani, Elena Maria Brach Del Prever
Publikováno v:
Journal of Clinical Oncology. 31:10572-10572
10572 Background: In STS third line treatment is poorly defined. However many patients (pts), after aggressive therapy as first and second line progress in their disease ask to be treated. Oral cyclophosphamide (CPM) was already used in breast cancer
Autor:
Alessandro Comandone, C. Oliva, Alessandra Linari, Gabriella Monasterolo, M. Turbiglio, Elena Giubellino, Elena Maria Brach Del Prever, G. Gino, Antonella Boglione, Raimondo Piana, P. Pochettino, Simona Chiadò Cutin, P. Bergnolo, Orietta Dal Canton, C. Faletti, Elisa Berno, Manuela Inguì
Publikováno v:
Journal of Clinical Oncology. 30:10055-10055
10055 Background: STS are 1% of malignant tumors in adults. Rarity, heterogeneity in presentation, low expertise in primary care physicians (PCP) or in general hospitals, organisation problems in specialized centers may cause a delay in both diagnosi
Autor:
Perrone, Francesco1 (AUTHOR) f.perrone@istitutotumori.na.it, Piccirillo, Maria Carmela1 (AUTHOR), Ascierto, Paolo Antonio2 (AUTHOR), Salvarani, Carlo3 (AUTHOR), Parrella, Roberto4 (AUTHOR), Marata, Anna Maria5 (AUTHOR), Popoli, Patrizia6 (AUTHOR), Ferraris, Laurenzia7 (AUTHOR), Marrocco-Trischitta, Massimiliano M.7 (AUTHOR), Ripamonti, Diego8 (AUTHOR), Binda, Francesca8 (AUTHOR), Bonfanti, Paolo9 (AUTHOR), Squillace, Nicola9 (AUTHOR), Castelli, Francesco10 (AUTHOR), Muiesan, Maria Lorenza10 (AUTHOR), Lichtner, Miriam11 (AUTHOR), Calzetti, Carlo12 (AUTHOR), Salerno, Nicola Duccio13 (AUTHOR), Atripaldi, Luigi4 (AUTHOR), Cascella, Marco14 (AUTHOR)
Publikováno v:
Journal of Translational Medicine. 11/22/2021, Vol. 19 Issue 1, p1-11. 11p.
Publikováno v:
Journal of Oncology Pharmacy Practice; Jun2010 Supplement, Vol. 16, p6-21, 16p